Skip To Main Content
Kevin Davies on Muck Rack

Kevin Davies

Verified
Washington, D.C.
As seen in: Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., The Waterstones Podcast, Medium, The Athletic, The New York Times, Nature, Post Outlook, The Daily Mirror, The Telegraph, TIME, PBS and
Author "CURVED AIR: A Biography of Sickle Cell Anemia and the Quest to Cure the First Molecular Disease" (Sept '26) Ed @GENBio @CRISPRJournal @GENbiotechjrnl

Get in touch with Kevin

Contact Kevin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Kevin Davies’s Biography

Read Full Bio →

Author, editor, publisher and writer with >25 years experience . Founding editor of Nature Genetics and Bio-IT World; currently Executive Editor of The CRISPR Journal and Editor-at-Lare with GEN

Articles

Fur Real: Biotech Startup Eliminates Major Dog Allergen in Beagle Pups Using CRISPR

|
By Kevin Davies Verified
| Genetic Engineering & Biotechnology News Verified
Home Topics Genome Editing Fur Real: Biotech Startup Eliminates Major Dog Allergen in Beagle Pups Using... Alfie and Bailey, two adorable gene-edited beagle pups, living their best lives without the major dog allergen gene. [Karolina Wojtasik] Researchers at Kindred Companion Sciences, a New York-based start-up company, have successfully used CRISPR-Cas9 gene editing to breed dogs lacking the primary protein responsible for human dog allergies.
Open in Who Shared Issue with article?

Fur Real: Biotech Startup Eliminates Major Dog Allergen in Beagle Pups Using CRISPR

|
By Kevin Davies Verified
| EIN News
Alfie and Bailey, two adorable gene-edited beagle pups, living their best lives without the major dog allergen gene. [Karolina Wojtasik] Researchers at Kindred Companion Sciences, a New York-based start-up company, have successfully used CRISPR-Cas9 gene editing to breed dogs lacking the primary protein responsible for human dog allergies.
Open in Who Shared Issue with article?

Sage Inks Publishing Deal with Causaly’s AI Platform Focusing on Drug Discovery Research

|
By Kevin Davies Verified
| Genetic Engineering & Biotechnology News Verified
In a new publishing deal, Causaly and Sage have announced a partnership to bring full-text scientific peer-reviewed literature into the world of AI-powered drug discovery research. According to Sage vice president Katie Metzler, who leads the publisher’s global licensing team, this deal follows a similar partnership that Sage struck in January 2026 with Consensus, an AI workspace for scientific research based in San Francisco.
Open in Who Shared View Duplicates (2) Issue with article?
See all 227 licensed articles (233 Total)

Awards

Guggenheim Fellowship

2017 - Science writing